Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
W. H. Wilson Tang, MD, is Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Director of the Center for Clinical Genomics, staff cardiologist and Research Director of the Section of Heart Failure and Cardiac Transplantation Medicine in the Sydell and Arnold Miller Family Heart & Vascular Institute at the Cleveland Clinic. As Director of the Cardiomyopathy program, Dr. Tang’s specialty interests include cardiomyopathy, heart failure, heart transplantation and mechanical circulatory assist devices.
Dr. Tang graduated magna cum laude with a Bachelor of Science degree in neural sciences from Brown University in Rhode Island, where he received an honorary one-year period of study of the natural sciences at Jesus College, Cambridge University, in England. Dr. Tang received his medical degree from Harvard Medical School, and completed his internship and residency in internal medicine and a research fellowship in heart failure at Stanford University Medical Center. This was followed by clinical cardiology fellowship training at the Cleveland Clinic, and an advanced clinical fellowship in heart failure and cardiac transplantation. He was appointed to Cleveland Clinic in 2004 as a Staff Physician in the Section of Heart Failure and Cardiac Transplantation Medicine. He is board-certified in internal medicine, cardiovascular medicine, and advanced heart failure and transplant cardiology. Dr. Tang is a Fellow of the American College of Cardiology (ACC) and a Fellow of the American Heart Association (AHA), and has committee appointments in the Heart Failure Society of America (HFSA). He serves as member of the writing committee for both ACC/AHA and HFSA clinical guidelines in the management of heart failure. He is also a member of the International Society of Heart and Lung Transplantation.
Dr. Tang is a clinician-scientist interested in clinical translational research, with joint appointments with the Department of Cell Biology and the Genomic Medicine Institute at Cleveland Clinic's Lerner Research Institute. His research has been funded by grants from American Heart Association, American College of Cardiology, and the National Institutes of Health (NIH). He leads the Cleveland GeneBank Study as well as the Cleveland Heart and Metabolic Prevention Study (CHAMPS) to investigate novel mechanisms in the development of heart diseases. Dr. Tang also has leadership roles in the NIH-sponsored Clinical and Translational Sciences Collaborative, particularly in the operations of the Clinical Research Unit Services and the Pilot Grant Program. Dr. Tang’s current research interests include the role of nitrative stress and counter-regulatory mechanisms in the development and progression of heart failure, integrative genomics and metabolomics in cardiomyopathy, cardio-renal physiology, and device-based treatment and remote monitoring in heart failure disease management. Dr. Tang is currently the Principal Investigator for the Cleveland Heart Failure Network as part of the National Heart Failure Clinical Research Network for translational clinical trials. Dr. Tang also serves as the Associate Director for Heart Failure Trials of C5Research, the academic research organization for the coordination of multicenter clinical trials. In 2013, he was elected as member of the American Society of Clinical Investigation, a national honor society for physician scientists for his contributions in heart failure and cardiovascular research.
Dr. Tang has authored over 350 published peer-reviewed manuscripts in medical and scientific journals as well as chapters in medical textbooks. He serves in the Editorial Boards for Journal of the American College of Cardiology Heart Failure, Circulation Heart Failure, American Heart Journal.
Cardiomyopathy, heart failure, heart transplantation, ventricular assist device, myocardial biopsy, cardiac catheterization, cancer heart disease, amyloidosis, cardiorenal syndrome, inherited cardiovascular diseases
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 5/15/2015, Dr. Tang has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.